TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06627283

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IMT
Description: Description: A pressure threshold loading device will be used: the POWERbreathe Medic (load range 10-90 cmH2O). Participants will be instructed to exhale passively during normal tidal breathing through the training device (until functional residual capacity) and to perform deep inspirations against the external load. The first week, the resistance will be fixed at 30% of the baseline measured maximal inspiratory pressure (MIP). Participants will be instructed to increase the resistance by 10% of the baseline set resistance each week.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EMT
Description: A pressure threshold loading device will be used: the POWERbreathe Ex1 EMT Medic (load range 10-90 cmH2O) or POWERbreathe Ex1 EMT MR (load range 35-175 cmH2O) depending on their baseline MEP measurement. Participants will be instructed to inhale quietly during normal tidal breathing through the training device and to perform rapid and deep exhalation against the external load. The first week, the resistance will be fixed at 30% of the baseline measured MEP. Participants will be instructed to increase the resistance by 10% of the baseline set resistance each week.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: A pressure threshold loading device will be used: the POWERbreathe Ex1 EMT Medic or MR, but with the resistance mechanism inside removed and replaced by a plastic ball. The same instructions will be given as for the EMT group, except that there will be no or minimal resistance (less than 6 cmH2O). There will be no change in resistance over the weeks.
Study: NCT06709898

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive job accommodation
Description: Job accommodation focused on the cognitive aspects at work
Study: NCT06726564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT027 cells suspension
Description: MT027: CRISPR/Cas9 edited B7H3-specific allogeneic CAR-T cells
Study: NCT06726200

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine + naloxone (Suboxone)
Description: Participants randomized to sublingual buprenorphine naloxone will initiate treatment based on clinical guidelines/standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Injection
Description: Participants randomized to injectable buprenorphine naloxone will receive a 300mg injection after receiving/tolerating a single 4/1 mg sublingual buprenorphine/naloxone dose
Study: NCT06725407

Intervention type: BEHAVIORAL
Intervention: Cesarean section
Description: In the study, the participants' postoperative hypothermia development status was monitored.
Study: NCT06726057

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imlementation strategies in conjunction with multicomponent hypertension intervention
Description: In this study, the researchers will develop and test strategies for the implementation and scale-up of a proven multicomponent hypertension intervention (MCHI) programme in Pakistan. Implementation strategies will be devised through an engagement process and will involve the use of implementation frameworks including the Consolidated Framework for Implementation Research (CFIR) to identify barriers and facilitators to the implementation of MCHI\&amp;amp; Expert Recommendations for Implementation Change (ERIC) to identify a set of implementation strategies addressing each barrier. Input for the development of strategies will be sought from the community, public health sector managers, general practitioners and community health workers. The implementation strategies will be used to randomise study clusters while MCHI will be implemented in both intervention and control arms.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multicomponent hypertension intervention
Description: The multicomponent hypertension intervention has four components as follows:~1. Training of community health workers (CHWs) in conducting health education sessions regarding hypertension, its risk factors, prevention, and health-seeking~2. Blood pressure (BP) monitoring and referral of hypertensive individuals by CHWs to general practitioners in primary care facilities~3. Training of general practitioners in primary care settings in BP monitoring and management of hypertension~4. Establishing hypertension triage counters and care coordinators in primary care facilities for the care of referred patients.
Study: NCT05745441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early Dinner tracer
Description: Stable isotope of oral \[2H31\] palmitate to measure fat oxidation, given with dinner before DLMO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Late Dinner tracer
Description: Stable isotope of oral \[2H31\] palmitate to measure fat oxidation, given with dinner after DLMO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Late Dinner tracer
Description: Stable isotope of oral \[2H31\] palmitate to measure fat oxidation, given with dinner after DLMO
Study: NCT06725381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB571
Description: SKB571 for injection is administered every 3 weeks (q3w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.
Study: NCT06725771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupleurum Plus Dragon Bone and Oyster Shell Decoction Combined with Sertraline
Description: Bupleurum Plus Dragon Bone and Oyster Shell Decoction and Sertraline are given to patients simultaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline Hydrochloride Tablets
Description: Sertraline are given to patients simultaneously
Study: NCT06727097

Intervention type: DIAGNOSTIC_TEST
Intervention: Posturography
Description: Successful completion of all four indices of the mCTSIB, without severe imbalance (i.e., near fall with safety harness and urgent knee to grab emergency handlebars) constitutes PSR +, non-completing on any of the index is noted as PSR -. Exploratorily, the average sway velocity index will be captured for each condition, to characterize sensory reweighting patterns.

Intervention type: DIAGNOSTIC_TEST
Intervention: Walking Speed
Description: The 10-meter walk test (10MWT) is the gold standard measure of post-stroke walking function that reflects overall mobility and health status. Method: Two 10MWT trials (using a stopwatch) are averaged and documented in meters/second. The functional ambulatory category (FAC) will be collected as supplement. Exploratorily: Participants will also perform the 10mWT (fast paced-FP) with two attempts. Both SS and FP will be performed over the Zeno Walkway Gait Analysis Mat, to capture supplementary spatiotemporal data.

Intervention type: DIAGNOSTIC_TEST
Intervention: Instrumented 7M Timed UP and GO
Description: This sub-aim will use iTUG to determine the effects of BLT on dynamic balance. In contrast to the traditional TUG, inclusion of wearable triaxial accelerometers and gyroscopes-placement test increases the sensitivity (87%) and specificity (87%) for identifying individuals prone to falls. Two trials are averaged and documented in seconds. Secondary analysis will be performed on data obtained from the sensors to determine (stride length, stride velocity, cadence, peak arm swing velocity, and turning velocity, during the task), to correlate with the TUG time/speed. Time points: Same as Posturography and 10 MWT.

Intervention type: OTHER
Intervention: Fall Event Records
Description: A robust fall incident journal elucidating the date, time, nature, and management of the fall event will be provided to all study participants for documentation. The study research coordinator will contact the patient/caregiver/facility to collect the data q2 weeks. A tally of the total number of fall events between visits will be recorded.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI (3T)
Description: Structural neuroimaging biomarkers:. The fractional anisotropy map from the primary fiber population in each voxel will be resampled to MNI space (using the warp derived from structural preprocessing) and projected onto a template white matter skeleton using local maxima to further optimize registration accuracy. Small vessel disease parameters, including white matter hyperintensities using the Fazekas scale and number/site of microhemorrhages, will be recorded for exploratory analyses.
Study: NCT06196567

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEMF
Description: Subjects will receive PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEMF
Description: Subjects will receive PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: do the exercise aimed at improving knee muscle strength,twice a week for 8 weeks before surgery
Study: NCT05934305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Matter Intervention
Description: This 5-session text-enhanced intervention is designed to mitigate the negative behavioral consequences of internalized stigma and shame among MSM and gender minority individuals with SUDs that perpetuate sub-optimal engagement in HIV self-care and consequently inconsistent viral suppression. The intervention involves five virtually delivered one-on-one therapy sessions focused on behavioral goal setting skill development and related self-efficacy, increasing meta-cognitive awareness(i.e.,non-judgmental awareness of emotions and cognitions), and teaching and reinforcing compassionate self-restructuring (i.e., self-compassion). Participants also receive daily text messages querying emotions during the one-on-one portion of the intervention. For eight weeks after the one-on-one portion, participants receive their compassionate self-statements via text in response to their indicated emotions. Participants will also receive phone-based resource navigation, as needed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Condition
Description: The control condition will involve five sessions of prerecorded asynchronous content related to local resources (e.g., information related to substance use treatment and other ancillary services).
Study: NCT06196567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: do the exercise aimed at improving knee muscle strength,twice a week for 8 weeks before surgery
Study: NCT05782595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic therapy
Description: • Each session was divided into three phases:~1. Aquatic environment adaptation phase~2. stretching phase~3. a phase of static and dynamic exercises for balance
Study: NCT06036069

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy
Description: * Standing with feet together while the therapist was sitting behind and manually locking the child knees.~* Step standing with the therapist behind the child.~* High step standing and trying to keep balanced. The child stood on exercise mattress.~* Single leg stance unilateral standing with assistance. The child was standing on exercise mattress.~* Standing on a declined surface by using wedge. The child was standing on wedge towards the descending direction.~* Standing with manual locking of the knees.~* Changing position.~* Gait training.~* Static and dynamic muscle contraction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy
Description: * Standing with feet together while the therapist was sitting behind and manually locking the child knees.~* Step standing with the therapist behind the child.~* High step standing and trying to keep balanced. The child stood on exercise mattress.~* Single leg stance unilateral standing with assistance. The child was standing on exercise mattress.~* Standing on a declined surface by using wedge. The child was standing on wedge towards the descending direction.~* Standing with manual locking of the knees.~* Changing position.~* Gait training.~* Static and dynamic muscle contraction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy
Description: * Standing with feet together while the therapist was sitting behind and manually locking the child knees.~* Step standing with the therapist behind the child.~* High step standing and trying to keep balanced. The child stood on exercise mattress.~* Single leg stance unilateral standing with assistance. The child was standing on exercise mattress.~* Standing on a declined surface by using wedge. The child was standing on wedge towards the descending direction.~* Standing with manual locking of the knees.~* Changing position.~* Gait training.~* Static and dynamic muscle contraction.
Study: NCT06426316

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood test
Description: 1 blood test of maximum 40 millilitres per patient

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood test
Description: 1 blood test of maximum 40 millilitres per patient
Study: NCT05230381

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continous infusion
Description: The 20mg/kg tranexamic acid will be diluted into a 50ml syringe and infused followed by 5mg/kg/h tranexamic acid infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single infusion
Description: The 20mg/kg tranexamic acid will be diluted into a 50ml syringe and infused followed by same volume of 0.9% saline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The 0.9% saline is administered with the same volume at the same speed as the other group.
Study: NCT04766177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bumetanide
Description: bumetanide 0.5 mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablets twice daily
Study: NCT05435261

Intervention type: PROCEDURE
Intervention: BKA
Description: Below Knee Amputation:~* Under spinal anesthesia~* BKA~* closure in layers (terminal closure) with suction drain.

Intervention type: PROCEDURE
Intervention: Debridement with Ex_Fix (salvage)
Description: Debridement and External Fixation (salvage):~* Under spinal anesthesia~* wound debridement and wash.~* external fixation.
Study: NCT05032781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-arterial cold saline, minocycline, and magnesium
Description: See study design
Study: NCT06401135

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: IMT will be conducted using a pressure threshold-loading device (POWERbreathe® Classic Low Resistance). The groups will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department. physiotherapist
Study: NCT04221100

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Radiograph interpretation for pulmonary abnormalities
Description: The pulmonary abnormalities detected by xrAI and included in the definition of abnormality are as follows: any linear scar or fibrosis, atelectasis, consolidation, abscess or cavity, nodule, pleural effusion, severe cases of emphysema and COPD (mild cases with hyperinflation but not significant emphysema are not flagged), pneumothorax.~Participants in the treatment group will interpret 500 images presented alongside the results of xrAI's processing in a dark room and asked to categorize each image into one of the following categories: lungs are clear, at least one pulmonary abnormality is present, not sure.~Participants in the control group will be asked to interpret the same 500 images as the treatment group but without xrAI's analysis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiograph interpretation for pulmonary abnormalities
Description: The pulmonary abnormalities detected by xrAI and included in the definition of abnormality are as follows: any linear scar or fibrosis, atelectasis, consolidation, abscess or cavity, nodule, pleural effusion, severe cases of emphysema and COPD (mild cases with hyperinflation but not significant emphysema are not flagged), pneumothorax.~Participants in the treatment group will interpret 500 images presented alongside the results of xrAI's processing in a dark room and asked to categorize each image into one of the following categories: lungs are clear, at least one pulmonary abnormality is present, not sure.~Participants in the control group will be asked to interpret the same 500 images as the treatment group but without xrAI's analysis.
Study: NCT06401135

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: IMT will be conducted using a pressure threshold-loading device (POWERbreathe® Classic Low Resistance). The groups will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department. physiotherapist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: IMT will be conducted using a pressure threshold-loading device (POWERbreathe® Classic Low Resistance). The groups will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department. physiotherapist
Study: NCT06089590

Intervention type: OTHER
Intervention: Non-interventional
Description: This study is non-interventional, patients will be enrolled when initiating a treatment through standard of care procedures.

Intervention type: OTHER
Intervention: Non-interventional
Description: This study is non-interventional, patients will be enrolled when initiating a treatment through standard of care procedures.

Intervention type: OTHER
Intervention: Non-interventional
Description: This study is non-interventional, patients will be enrolled when initiating a treatment through standard of care procedures.

Intervention type: OTHER
Intervention: Non-interventional
Description: This study is non-interventional, patients will be enrolled when initiating a treatment through standard of care procedures.

Intervention type: OTHER
Intervention: Non-interventional
Description: This study is non-interventional, patients will be enrolled when initiating a treatment through standard of care procedures.
Study: NCT06005311

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microfluidic chip
Description: The Sperm Separation Device - ZyMōt Multi 850µL (ZyMōt Fertility, Inc) will be used. The microfluidics chamber will be used according to the manufacturer's instructions. 850 μL of the semen sample will be inserted into the inlet port of the device and 750 μL of fertilization media will be inserted into the outlet port. The device with the semen sample inside will be incubated in 6% CO2 at 37°C. After 30 min, 500 μL of the sample at the outlet port will be removed from the outlet port and pipetted into a labelled test tube.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Density-gradient centrifugation
Description: After liquefaction, sperm preparation will be completed by a discontinuous density gradient centrifugation method, using Pureception (CooperSurgical, Denmark) sperm density gradient media. The resulting sperm pellet after centrifugation will be washed once with the sperm washing medium (G-IVF Plus, Vitrolife, Sweden) The washed spermatozoa will be resuspended with the same medium, adjusting the final volume to 0.5 mL.
Study: NCT06089590

Intervention type: OTHER
Intervention: Non-interventional
Description: This study is non-interventional, patients will be enrolled when initiating a treatment through standard of care procedures.
Study: NCT05185791

Intervention type: OTHER
Intervention: Pre-ERAS® phase (current clinical practice)
Description: Descriptive recordings of pre-intra-post-operative clinical endpoints and demographic parameters.

Intervention type: OTHER
Intervention: Post-ERAS® implementation phase
Description: Descriptive recordings of pre-intra-post-operative clinical endpoints and demographic parameters.
Study: NCT05676541

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complex intervention to enhance care for patients with multimorbidity in general practice consisting of an extended overview consultation and supporting elements
Description: The intervention consists of 1) an extended overview consultation lasting 30-45 minutes in general practice, 2) access to cross-sectoral video conferences with secondary care specialists and 3) an instruction material for GPs on how to organize the intervention and 4) an adaptive toolbox to support elements in the intervention (not yet developed)
Study: NCT04920045

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red blood cell transfusion
Description: All RBC transfusions will be administered in 1 unit increments to maintain patients' Hb concentration above the trial arm threshold they are randomized to. All transfusions will be followed by a Hb measure and an additional unit(s) of RBC's will only be transfused if there is documentation of the patient's Hb concentration below the trial arm threshold they are randomized to. However, in the case of life-threatening bleeding clinicians will be able to transfuse patients without first checking a patient's Hb concentration. Once randomized, patients will be man-aged according to protocol until hospital discharge independent of transfer to another service and/or specialized hospital ward.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red blood cell transfusion
Description: All RBC transfusions will be administered in 1 unit increments to maintain patients' Hb concentration above the trial arm threshold they are randomized to. All transfusions will be followed by a Hb measure and an additional unit(s) of RBC's will only be transfused if there is documentation of the patient's Hb concentration below the trial arm threshold they are randomized to. However, in the case of life-threatening bleeding clinicians will be able to transfuse patients without first checking a patient's Hb concentration. Once randomized, patients will be man-aged according to protocol until hospital discharge independent of transfer to another service and/or specialized hospital ward.
Study: NCT04990128

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Aspire Needle + Emcyte PureBMC
Description: The Aspire Needle will be utilized to extract the bone marrow and the Emcyte PureBMC will be used to concentrate bone marrow aspirate. The final concentrate will be injected into the hip.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: 40 mg (1 mL) triamcinolone and 4 cc of lidocaine 1% that will be injected into the hip.